Dr. Alahmadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
The James Cancer Hospital and Solove Research Institute
460 W 10th Ave
Columbus, OH 43210Phone+1 216-844-2562
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2014 - 2017
- USCDMAS-CR, Master of Advanced Studies in Clinical Research, 2013 - 2014
- King Abdulaziz University College of MedicineClass of 2011, MBBS
Certifications & Licensure
- OH State Medical License 2020 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2020 Jun 17
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.Kylie Fletcher, Alessio Cortellini, Teja Ganta, Roma Kankaria, Haocan Song
Cancer Letters. 2024-08-01 - CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.Adam Khorasanchi, Songzhu Zhao, Lai Wei, Mingjia Li, Kevin Ho
Journal of the National Comprehensive Cancer Network. 2024-04-05 - 3 citationsAssociation Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.Alexander Wong, Maria Riley, Songzhu Zhao, Jessica Zimmer, Matthew Viveiros
Journal of the National Comprehensive Cancer Network. 2023-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: